Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe Asthma

Figures & data

Table 1 Characteristics for Patients Who Were Eligible, Enrolled, and Initiated Biologics After Enrollment

Characteristic	Eligible Patients (N = 4582)	All Enrolled (n = 3574)	Initiated Biologics after Enrollment (n = 225)
Age at screening, years
Mean (SD)	54.8 (14.9)	54.4 (14.7)	53.1 (14.1)
Median (range)	56.0 (18–89)	56.0 (18–89)	54.0 (18–87)
Female, %	68.9	68.7	64.4
Race, %
White	N/A	73.5	72.4
Black	N/A	17.6	20.0
Asian	N/A	1.8	1.8
Other^a	N/A	3.2	2.2
Not reported	N/A	3.9	3.6
Missing	N/A	0.1	0.0
Hispanic or Latino ethnicity, %	N/A	10.0	5.8
Insurance, %
Commercial	56.1	57.4	59.1
Medicare	24.8	23.5	21.8
Medicaid	11.1	11.2	13.8
Uninsured	1.1	1.0	1.3
Other^b	6.8	6.9	3.6
Missing	0.1	0.1	0.4
Confirmed exacerbations per patient during 12 months before enrollment
Mean (SD)	1.2 (1.6)	1.1 (1.6)	1.6 (1.7)
Median (range)	1.0 (0–10)	1.0 (0–10)	1.0 (0–10)
Percent with ≥1 exacerbation during 12 months before enrollment (%)	52.4	51.9	68.0
Screening/enrollment treatment class, %
Uncontrolled on high-dose ICS/LABA only	35.1	30.2	60.9
Any monoclonal antibody	54.3	58.2	20.9
Any monoclonal antibody and mSCS	6.2	7.1	4.4
Systemic corticosteroids or immunosuppressant only	4.4	4.4	13.8

Notes: ^aIncludes Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, and Other. ^bOther insurance including other government insurance.

Abbreviations: ICS, inhaled corticosteroids; LABA, long-acting beta-agonist; mSCS, maintenance systemic corticosteroids; SD, standard deviation.

Figure 1 SGRQ scores 6 months before and 12 to 18 months after initiation of biologics. (A) All patients (n = 76). (B) Patients using anti-IgE therapy (n = 13). (C) Patients using anti–IL-5/5R/4Rs or anti-thymic stromal lymphopoietin therapy (n = 63).

Abbreviations: IgE, immunoglobulin E; IL, interleukin; SGRQ, St. George’s Respiratory Questionnaire.

Figure 2 Specific impairments reported by patients 6 months before and 12 to 18 months after initiation of biologics, from greatest to least improvement (n = 76). Results limited to those specific impairments reported by ≥ 50% of patients before biologic initiation.